The post XRP ETF Approval Timeline: October and November Could Change Everything appeared first on Coinpedia Fintech News The XRP community is bracing for a decisive stretch this fall as the U.S. Securities and Exchange Commission (SEC) prepares to deliver long-awaited rulings on several spot XRP ETF applications. With multiple deadlines scheduled for October and November 2025, the coming months could either cement XRP’s place in mainstream finance or deal a heavy blow …The post XRP ETF Approval Timeline: October and November Could Change Everything appeared first on Coinpedia Fintech News The XRP community is bracing for a decisive stretch this fall as the U.S. Securities and Exchange Commission (SEC) prepares to deliver long-awaited rulings on several spot XRP ETF applications. With multiple deadlines scheduled for October and November 2025, the coming months could either cement XRP’s place in mainstream finance or deal a heavy blow …

XRP ETF Approval Timeline: October and November Could Change Everything

XRP ETF Approval

The post XRP ETF Approval Timeline: October and November Could Change Everything appeared first on Coinpedia Fintech News

The XRP community is bracing for a decisive stretch this fall as the U.S. Securities and Exchange Commission (SEC) prepares to deliver long-awaited rulings on several spot XRP ETF applications. With multiple deadlines scheduled for October and November 2025, the coming months could either cement XRP’s place in mainstream finance or deal a heavy blow to investor hopes.

October’s Cluster of XRP ETF Decisions

The SEC will issue a series of rulings in mid-October:

  • October 18 – Grayscale’s XRP ETF ruling
  • October 19 – 21Shares’ XRP ETF ruling
  • October 20 – Bitwise’s XRP ETF ruling
  • October 23 – CoinShares and Canary Capital XRP ETF rulings
  • October 24 – WisdomTree’s XRP ETF ruling

This packed schedule means XRP could dominate headlines for weeks, with each ruling acting as a potential market catalyst. Even a single approval could spark inflows, while multiple approvals in quick succession might trigger a larger rally.

The action doesn’t stop in October. Franklin Templeton’s application, one of the most closely watched given the firm’s influence in traditional finance, is due on November 14. Approval of this fund could draw significant attention from mainstream investors and asset managers well beyond the crypto space.

Divided Opinions on Institutional Demand

Not everyone believes these ETFs will transform XRP’s adoption. 

On X, analyst AdrianoFeria.eth argued that the launch could backfire, stating: 

Critics argue XRP lacks the strong narratives that help Bitcoin thrive as “digital gold” or Ethereum as the backbone of decentralized applications. From this perspective, ETFs may launch but still struggle to attract serious inflows.

  • Also Read :
  •   How High Will XRP Price Go in September 2025?
  •   ,

Optimists see things differently. Canary Capital CEO Steven McClurg predicts an XRP ETF could attract $5 billion within its first month, potentially outperforming Ethereum ETFs in the financial sector. 

Supporters argue XRP’s efficiency in cross-border payments makes it a natural fit for institutions once the right investment vehicle is available.

SEC’s Wider Crypto ETF Wave

XRP is not alone in this race. Bloomberg analyst James Seyffart notes the SEC is reviewing 92 crypto ETF applications, covering assets from Solana and Cardano to meme coins like Bonk and Trump’s token. 

Seyffart estimates a 95% chance of approval for XRP, Solana, and Litecoin ETFs in 2025, making this fall a possible turning point not just for XRP, but for the broader altcoin market.

Never Miss a Beat in the Crypto World!

Stay ahead with breaking news, expert analysis, and real-time updates on the latest trends in Bitcoin, altcoins, DeFi, NFTs, and more.

bell icon Subscribe to News
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23